Tulopafant is a platelet activating factor (PAF) antagonist.
Preincubation of neutrophils with Tulopafant (RP 59227) results in a concentration-dependent decrease in chemiluminescence produced by PAF primed cells[1].
Tulopafant (RP 59227) effectively reduces myocardial infarct size and reduces the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs[1].Histological examination reveals marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals are pretreated with Tulopafant[2].
[1]. Auchampach JA, et al. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. Basic Res Cardiol. 1998 Oct;93(5):361-71. [2]. O'Hair DP, et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993 May;7(1):79-84.